medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2019, Número 1

<< Anterior

Ann Hepatol 2019; 18 (1)


Implications of Manganese in Chronic Acquired Hepatocerebral Degeneration

Rajoriya N, Brahmania M, Feld JJ

Idioma: Ingles.
Referencias bibliográficas: 41
Paginas: 274-278
Archivo PDF: 135.81 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Nadaska G, Lesny J, Michalik I. Environmental aspect of manganese chemistry. HEJ 2012: ENV-100702A: 1-16.

  2. Aschner M, Guilarte TR, Schneider JS, Zheng W. Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol 2007; 221: 131-47.

  3. Crossgrove J, Zheng W. Manganese toxicity upon overexposure. NMR Biomed 2004; 17: 544-53.

  4. Cowan DM, Fan Q, Zou Y, Shi X, Chen J, Aschner M, Rosenthal FS, et al. Manganese exposure among smelting workers: blood manganese-iron ratio as a novel tool for manganese exposure assessment. Biomarkers 2009; 14: 3-16.

  5. Korczynski RE. Occupational health concerns in the welding industry. Appl Occup Environ Hyg 2000; 15: 936-45.

  6. Butterworth RF. Parkinsonism in cirrhosis: pathogenesis and current therapeutic options. Metab Brain Dis 2013; 28: 261-7.

  7. Scheuhammer AM, Cherian MG. The influence of manganese on the distribution of essential trace elements. II. The tissue distribution of manganese, magnesium, zinc, iron, and copper in rats after chronic manganese exposure. J Toxicol Environ Health 1983; 12: 361-70.

  8. Woerkom W. La cirrhose heaptique avec alterations dan les centres nerveux evoluant chez des sujets d’age moyen. Nouvelle Iconographie de la Salpetrie. Clinique maladies Systeme Nerveux 1914; 7: 41-5.

  9. Victor M, Adams R, Cole M. The acquired (non-Wilsonian) type of chronic hepatocerebral degeneration. Medicine (Baltimore) 1965; 44: 345-96.

  10. Stracciari A, Baldin E, Cretella L, Delaj L, D’Alessandro R, Guarinoa M. Chronic Acquired hepatocerebral degeneration: effects of liver transplantation. Neurol Sci 2011; 32: 411-5.

  11. Pinarbasi B, Kaymakoglu S, Matur Z, Akyuz F, Demir K, Besisik F, Ozdil S, et al. Are acquired hepatocerebral degeneration and hepatic myelopathy reversible? J Clin Gastroenterol 2009; 43: 176-81.

  12. Fernández-Rodriguez R, Contreras A, De Villoria JG, Grandas F. Acquired hepatocerebral degeneration: clinical characteristics and MRI findings. Euro J Neurol 2010; 17: 1463-70.

  13. Soffer D, Sherman Y, Tur-Kaspa R, Eid A. Acquired hepatocerebral degeneration in a liver transplant recipient. Acta Neuropathol 1995; 90: 107-11.

  14. Butterworth RF. Neuronal cell death in hepatic encephalopathy. Metab Brain Dis 2007; 22: 309-20.

  15. Felipo V, Butterworth RF. Mitochondrial dysfunction in acute hyperammonemia. Neurochem Int 2002; 40: 487-91.

  16. Butterworth RF. Metal Toxicity, Liver disease and neurodegeneration. Neurotox Res 2010; 18: 100-5.

  17. Yin Z, Aschner JL, dos Santos AP, Aschner M. Mitochondrial- dependent manganese neurotoxicity in rat primary astrocyte cultures. Brain Res 2008; 1203: 1-11.

  18. Hazell AS, Desjardins P, Butterworth RF. Chronic exposure of rat primary astrocyte cultures to manganese results in increased binding sites for the ‘peripheral-type’ benzodiazepine receptor ligand 3 H-PK 11195. Neurosci Lett 1999; 271: 5-8.

  19. Giguère JF, Hamel E, Butterworth RF. Increased densities of binding sites for the ‘peripheral-type’ benzodiazepine receptor ligand [3 H] PK 11195 in rat brain following portacaval anastomosis. Brain Res 1992; 585: 295-8.

  20. Lavoie J, Layrargues GP, Butterworth RF. Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. Hepatology 1990; 11: 874-8.

  21. Hazell AS, Norenberg MD. Manganese decreases glutamate uptake in cultured astrocytes. Neurochem Res 1997; 22: 1443-7.

  22. Ferrara J, Jankovic J. Acquired hepatocerebral degeneration. J Neurol 2009; 256: 320-32.

  23. Stracciari A, Mattarozzi K, D’Alessandro R, Baldin E, Guarino M. Cognitive functioning in chronic acquired hepatocerebral degeneration. Metabol Brain Dis 2008; 23: 155-60.

  24. Mendez MF. Hepatic dementia or acquired hepatocerebral degeneration. J Am Geriatr Soc 1989; 37: 259-60.

  25. Lee J, Lacomis D, Comu S, Jacobsohn J, Kanal E. Acquired hepatocerebral degeneration: MR and pathologic findings. Am J Neuroradiol 1998; 19: 485-7.

  26. Pujol A, Pujol J, Graus F, Rimola A, Peri J, Mercader JM, Garcia- Pagan JC, et al. Hyperintense globus pallidus on T1- weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 1993; 43: 65-9.

  27. Devenyi AG, Barron TF, Mamourian AC. Dystonia, hyperintense basal ganglia, and high whole blood manganese levels in Alagille’s syndrome. Gastroenterology 1994; 106: 1068-71.

  28. Tuschl K, Clayton PT, Gospe SM, Gulab S, Ibrahim S, Singhi P, Aulakh R, et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Genet 2012; 90: 457-66.

  29. Gospe SM, Caruso RD, Clegg MS, Keen CL, Pimstone NR, Ducore JM, Gettner SS, et al. Paraparesis, hypermanganesaemia, and polycythaemia: a novel presentation of cirrhosis. Arch Dis Child 2000; 83: 439-42.

  30. Lechpammer M, Clegg MS, Muzar Z, Huebner PA, Jin LW, Gospe SM. Pathology of inherited manganese transporter deficiency. Ann Neurol 2014; 75: 608-12.

  31. Spahr L, Butterworth RF, Fontaine S, Bui L, Therrien G, Milette PC, Lebrun LH, et al. Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 1996; 24: 1116-20.

  32. Quadri M, Federico A, Zhao T, Breedveld GJ, Battisti C, Delnooz C, Severijnen LA, et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet 2012; 90: 467-77.

  33. Tuschl K, Mills PB, Parsons H, Malone M, Fowler D, Bitner- Glindzicz M, Clayton PT. Hepatic cirrhosis, dystonia, polycythaemia and hypermanganesaemia-a new metabolic disorder. J Inherit Metab Dis 2008; 31: 151-63.

  34. Kok B, Foxton MR, Clough C, Shawcross DL. Rifaximin is an efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy. Hepatology 2013; 58: 1516-7.

  35. Hisahara S, Matsushita T, Kitamura M, Mezawa S, Nonaka M, Imai T, Shimohama S. Long-term clinical and radiological improvement of chronic acquired hepatocerebral degeneration after obliteration of portosystemic shunt: Report of a case. J Neurol Sci 2014; 346: 303-6.

  36. Powell EE, Pender MP, Chalk JB, Parkin PJ, Strong R, Lynch S, Kerlin P, et al. Improvement in chronic hepatocerebral degeneration following liver transplantation. Gastroenterology 1990; 98: 1079-82.

  37. Servin-Abad L, Tzakis A, Schiff ER, Regev A. Acquired hepatocerebral degeneration in a patient with HCV cirrhosis: complete resolution with subsequent recurrence after liver transplantation. Liver Transpl 2006; 12: 1161-5.

  38. Parkes JD, Murray-Lyon IM, Williams RO. Neuropsychiatric and electroencephalographic changes after transplantation of the liver. QJ Med 1970; 39: 515-27.

  39. Stracciari A, Guarino M, Pazzaglia P, Marchesini G, Pisi P. Acquired hepatocerebral degeneration: full recovery after liver transplantation. J Neurol Neurosurg Psychiarty 2001; 70: 136-7.

  40. Shulman LM, Minagar A, Weiner WJ. Reversal of parkinsonism following liver transplantation. Neurology 2003; 60: 519.

  41. Wijdicks EF, Wiesner RH. Acquired (non-Wilsonian) hepatocerebral degeneration: complex management decisions. Liver Transpl 2003; 9: 993-4.




2020     |     www.medigraphic.com